A case study in misidentification of cancer cell lines: MCF-7/AdrR cells (re-designated NCI/ADR-RES) are derived from OVCAR-8 human ovarian carcinoma cells

Cancer Letters

Volumn 245, Issue 1-2, 2007, Pages 350-352

  Liscovitch, Mordechai ^a   Ravid, Dana ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Cancer; Cell lines; Genotyping; MCF 7 AdrR; Multidrug resistance; NCI ADR RES; OVCAR 8

Indexed keywords

ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL CULTURE; CANCER GENETICS; CELL STRAIN MCF 7; HEALTH CARE ORGANIZATION; HUMAN; KARYOTYPE; NOMENCLATURE; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 33845681037     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.01.013     Document Type: Note

References (21)

1. Batist G., Tulpule A., Sinha B.K., Katki A.G., Myers C.E., and Cowan K.H. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J. Biol. Chem. 261 (1986) 15544-15549
2. Cowan K.H., Batist G., Tulpule A., Sinha B.K., and Myers C.E. Similar biochemical changes associated with multidrug resistance in human breast cancer cells and carcinogen-induced resistance to xenobiotics in rats. Proc. Natl Acad. Sci. USA 83 (1986) 9328-9332
3. Monks A., Scudiero D., Skehen P., Shoemaker R., Paull K., Vistica D., et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl Cancer Inst. 83 (1991) 757-766
4. Weinstein J.N., Myers T.G., O'Connor P.M., Friend S.H., Fornace Jr. A.J., Kohn K.W., et al. An information-intensive approach to the molecular pharmacology of cancer. Science 275 (1997) 343-349
5. Scherf U., Ross D.T., Walthan M., Smith L.H., Lee J.K., Tanabe L., et al. A gene expression database for the molecular pharmacology of cancer. Nat. Genet. 24 (2000) 236-244
6. Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P., et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat. Genet. 24 (2000) 227-235
7. Nishizuka S., Charboneau L., Young L., Major S., Reinhold W.C., Waltham M., et al. Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc. Natl Acad. Sci. USA 100 (2003) 14229-14234
8. Scudiero D.A., Monks A., and Sausville E.A. Cell line designation change: multidrug-resistant cell line in the NCI anticancer screen. J. Natl Cancer Inst. 90 (1998) 862
9. Pirnia F., Breuleux M., Schneider E., Hochmeister M., Bates S.E., Marti A., et al. Uncertain identity of doxorubicin-resistant MCF-7 cell lines expressing mutated p53. J. Natl Cancer Inst. 92 (2000) 1535-1536
10. Foster B.J., Grotzinger K.R., McKoy W.M., Rubinstein L.V., and Hamilton T.C. Modulation of induced resistance to adriamycin in two human breast cancer cell lines with tamoxifen or perhexiline maleate. Cancer Chemother. Pharmacol. 22 (1988) 147-152
11. Wosikowski K., Regis J.T., Robey R.W., Alvarez M., Buters J.T., Gudas J.M., et al. Normal p53 status and function despite the development of drug resistance in human breast cancer cells. Cell Growth Differ. 6 (1995) 1395-1403
12. Ogretmen B., and Safa A.R. Expression of the mutated p53 tumor suppressor protein and its molecular and biochemical characterization in multidrug resistant MCF-7/Adr human breast cancer cells. Oncogene 14 (1997) 499-506
13. Janicke R.U., Sprengart M.L., Wati M.R., and Porter A.G. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J. Biol. Chem. 273 (1998) 9357-9360
14. Devarajan E., Chen J., Multani A.S., Pathak S., Sahin A.A., and Mehta K. Human breast cancer MCF-7 cell line contains inherently drug-resistant subclones with distinct genotypic and phenotypic features. Int. J. Oncol. 20 (2002) 913-920
15. Mehta K., Devarajan E., Chen J., Multani A., and Pathak S. Multidrug-resistant MCF-7 cells: an identity crisis?. J. Natl Cancer Inst. 94 (2002) 1652-1654
16. Hathout Y., Gehrmann M.L., Chertov A., and Fenselau C. Proteomic phenotyping: metastatic and invasive breast cancer. Cancer Lett. 210 (2004) 245-253
17. O'Connor P.M., Jackman J., Bae I., Myers T.G., Fan S., Mutoh M., et al. Characterization of the p53 tumor suppressor pathway in cell lines of the national cancer institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 57 (1997) 4285-4300
18. MacLeod R.A., Dirks W.G., Matsuo Y., Kaufmann M., Milch H., and Drexler H.G. Widespread intraspecies cross-contamination of human tumor cell lines arising at source. Int. J. Cancer 83 (1999) 555-563
19. Masters J.R., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G., Packer P., et al. Short tandem repeat profiling provides an international reference standard for human cell lines. Proc. Natl Acad. Sci. USA 98 (2001) 8012-8017
20. Thompson E.W., Waltham M., Ramus S.J., Hutchins A.M., Armes J.E., Campbell I.G., et al. LCC15-MB cells are MDA-MB-435: a review of misidentified breast and prostate cell lines. Clin. Exp. Metastasis 21 (2004) 535-541
21. UKCCCR guidelines for the use of cell lines in cancer research, Br. J. Cancer 82 (2000) 1495-1509.